Current challenges in applying gene-driven therapies in clinical lung cancer practice

Table 1 Number of tested patients during years 2016-2019

	Pyrosequencing (all patients)	NGS(all patients)	Lung cancer	cfDNA	ALK (IHC)	ROS-1 (IHC)
2016	128	1	39	5	8	0
2017	82	29	38	10	6	0
2018	0	125	49	28	51	0
2019	0	93	33	12	34	16

NGS: Next generation sequencing; ALK: Anaplastic lymphoma kinase; IHC: Immunohistochemistry.

Table 2 Number of mutations found in genetic testing of lung cancer patients

	EGFR-pos	BRAF pos	KRAS pos	cfDNA EGFR-pos	ALK-pos	ROS-1-pos
2016	2 (5%)	NR	NR	1 (20%)	0	0
2017	2 (5%)	NR	NR	2 (20%)	0	0
2018	6 (12%)	1 (2%)	9 (18%)	6 (21%)	2 (4%)	0
2019	6 (18%)	2 (6%)	10 (30%)	3 (25%)	0	0

EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; NR: Not reported.